Company profile: Novacyt
1.1 - Company Overview
Company description
- Provider of in vitro and molecular diagnostic tests and cellular diagnostics, with a growing portfolio in cancer and infectious disease, offering diagnostics product development, commercialisation, and contract design and manufacturing via Primerdesign and Lab21 Products.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Novacyt
BiPar Sciences
HQ: United States
Website
- Description: Provider of PARP inhibitor-based cancer therapies, developing BSI-201, an experimental PARP inhibitor in mid-stage trials for advanced breast cancer, ovarian cancer, and other tumors; based in Brisbane, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BiPar Sciences company profile →
Inanovate
HQ: United States
Website
- Description: Provider of multiplexed protein quantification and longitudinal assay screening technologies for detecting and measuring multiple proteins, including the Bio-ID real-time platform (high sensitivity confocal imaging and microfluidics) and LAS time-resolved fluorescent assays. Also offers a breast cancer blood test to improve mammography accuracy and detect recurrence, Bio-ID services, an alliance program for LAS assays, and the i-Slide protein microarray substrate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inanovate company profile →
Kymera Therapeutics
HQ: United States
Website
- Description: Provider of targeted protein degradation therapeutics, leveraging TPD to eliminate disease-causing proteins, developing investigational degraders KT-474 (IRAK4) in Phase 2 for hidradenitis suppurativa and atopic dermatitis; KT-333 (STAT3) in Phase 1 for hematological malignancies and solid tumors; and KT-253 (MDM2) in Phase 1 for high-grade myeloid malignancies, lymphomas, and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kymera Therapeutics company profile →
Xcovery
HQ: United States
Website
- Description: Provider of low-toxicity, molecular-targeted oral cancer therapeutics, including Ensartinib for ALK-positive non-small cell lung cancer and Vorolanib, a VEGFR/PDGFR tyrosine kinase inhibitor for solid tumors such as renal cell carcinoma. Conducts clinical trials, seeks partnerships to launch Ensartinib globally and advance Vorolanib in combination therapy, and offers patient information and support resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xcovery company profile →
NanoSmart Pharmaceuticals
HQ: United States
Website
- Description: Provider of platform drug delivery technologies for solid-tumor cancers, including a human-derived Anti-Nuclear Antibody targeting necrotic tumor tissue, ANA-conjugated lipid nanoparticles for direct API delivery to tumor sites, and a thermally sensitive nanoemulsion enabling stable storage and release at body temperature, plus licensing and partnerships to enhance existing cancer drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoSmart Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Novacyt
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Novacyt
2.2 - Growth funds investing in similar companies to Novacyt
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Novacyt
4.2 - Public trading comparable groups for Novacyt
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →